Sign up here to receive news updates via email.
-
July 14, 2021 |
Media, Press Releases
BERG To Present Latest Glioblastoma [GBM] Treatment Data At Society For Neuro-Onocology 2021 Meeting
read moreBERG’s presentations will explore mechanics of BERG’s Interrogative Biology® Platform and application of BPM 31510’s anti-cancer influence on GBM News provided by BERG Health Jul 14, 2021, 09:30 ET FRAMINGHAM, Mass., July 14, 2021 /PRNewswire/ — BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop…
-
June 2, 2021 |
Media, Press Releases
BERG to Present Phase 1 Results of BPM 31510-IV and Identifies Therapeutic Opportunities for Recurrent GBM Patients at 2021 American Society of Clinical Oncology (ASCO) Meeting
read moreResults Will Advance Understanding of Potential Predictive Responses of Markers in High-Grade Brain Cancer Patients News provided by BERG Health Jun 02, 2021, 08:30 ET FRAMINGHAM, Mass., June 2, 2021 /PRNewswire/ — BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, today announced results from…
-
March 22, 2021 |
Media, Press Releases
BERG To Conduct Phase Two Trial For Treatment Of Deadly Glioblastoma Multiforme [GBM]
read moreFDA Authorizes use of BPM31510 in Neo-Adjuvant and Concurrent Standard of Care Combination in Newly Diagnosed GBM Patients in a Phase 2 Clinical Trial News provided by BERG Health Mar 22, 2021, 14:00 ET FRAMINGHAM, Mass., March 22, 2021 /PRNewswire/ — BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to…
-
December 15, 2020 |
Media, Press Releases
BERG Deepens Research Collaboration With AdventHealth To Advance Aging, Metabolism and Nash Research
read morePartnership Will Address Significant Unmet Medical Needs News provided by BERG Health Dec 15, 2020, 09:00 ET FRAMINGHAM, Mass., Dec. 15, 2020 /PRNewswire/ — BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, today announced a research collaboration with AdventHealth, a leading non-profit healthcare…
-
November 23, 2020 |
Media, Press Releases
BERG And AdventHealth Announce New Partnership To Decrease Mortality Rate Of COVID-19 Patients Throughout Hot Zones Across USA
read morePartnership will use AI to match patients with the best treatments based on their biological profiles. Work in Florida will serve as a model for the rest of the USA News provided by BERG Health Nov 23, 2020, 09:00 ET FRAMINGHAM, Mass., Nov. 23, 2020 /PRNewswire/ — BERG, a clinical-stage biotech that employs…
-
September 18, 2020 |
Media, Press Releases
BERG To Present Discovery/Validation Of Biomarkers Associated With Survival In Pancreatic Ductal Adenocarcinoma (PDAC) Treated With BPM 31510-IV At The European Society For Medical Oncology (ESMO) 2020 Congress
read moreInterrogative Biology Platform® employed to produce high-fidelity characterization of pancreatic cancer and identify two potential biomarkers between survival (OS), stable disease (SD), and progressive disease (PD) in a Phase 2 trial News provided by BERG Health Sep 18, 2020, 15:49 ET FRAMINGHAM, Mass., Sept. 18, 2020 /PRNewswire/ — BERG, a clinical-stage biotech that employs artificial intelligence…
